Description
Takhzyro (lanadelumab) is a prescription medication used to prevent hereditary angioedema (HAE) attacks in individuals aged 12 years and older. HAE is a rare disease that causes swelling in different parts of the body, including the throat, stomach, and limbs. Takhzyro is a monoclonal antibody that works by blocking the activity of kallikrein, a serine protease that plays a key role in the pathophysiology of HAE.
Uses:
Takhzyro is used to prevent HAE attacks in people with HAE aged 12 years and older. This medication is not used to treat an acute HAE attack.
Storage Conditions:
Takhzyro should be stored in a refrigerator between 2°C to 8°C (36°F to 46°F) in its original carton to protect it from light. Do not freeze or shake the medication.
Mechanism of Action:
Takhzyro is a monoclonal antibody that targets kallikrein, a serine protease involved in the activation of the bradykinin pathway, which is implicated in the pathophysiology of HAE. By blocking the activity of kallikrein, Takhzyro reduces the production of bradykinin, thus preventing the swelling associated with HAE.
HOW TO USE:
Takhzyro is administered as a subcutaneous injection once every two to four weeks, depending on your doctor’s recommendation. The medication should be injected into the fatty tissue of your upper arm or abdomen, following the instructions provided by your doctor or nurse. You should not inject Takhzyro into a vein or muscle.
Precautions:
Before using Takhzyro, tell your doctor if you have any allergies or have ever had an allergic reaction to this medication or any of its ingredients. Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. Takhzyro may pass into breast milk, and its effects on a nursing infant are not known.
Drug Interactions:
There are no known drug interactions with Takhzyro.
Contraindications:
Do not use Takhzyro if you have ever had an allergic reaction to this medication or any of its ingredients.
Overdose:
In case of an overdose, seek emergency medical attention.
Adverse Reactions:
The most common side effects of Takhzyro include injection site reactions such as pain, redness, and swelling, headache, and nausea. Some people may experience hypersensitivity reactions such as rash, hives, and difficulty breathing. If you experience any adverse reactions, inform your doctor or seek medical attention immediately.
In conclusion, Takhzyro is a monoclonal antibody medication used to prevent HAE attacks in people aged 12 years and older. It works by blocking the activity of kallikrein, a serine protease involved in the pathophysiology of HAE. Before using Takhzyro, inform your doctor of any allergies or pregnancy status. The medication is administered as a subcutaneous injection once every two to four weeks. However, Takhzyro is not used to treat an acute HAE attack. The most common side effects of Takhzyro include injection site reactions, headache, and nausea. If you experience any adverse reactions, inform your doctor or seek medical attention immediately.
Reviews
There are no reviews yet.